argenx (ARGX) Stock Forecast & Price Target

$665.60 -4.80 (-0.72%)

As of 01/14/2025 04:00 PM Eastern

argenx - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 22 Analyst Ratings

Sell
0

Hold
3

Buy
19

Based on 22 Wall Street analysts who have issued ratings for argenx in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 22 analysts, 3 have given a hold rating, 18 have given a buy rating, and 1 has given a strong buy rating for ARGX.

Consensus Price Target

$658.39
-1.08% Downside

According to the 22 analysts' twelve-month price targets for argenx, the average price target is $658.39. The highest price target for ARGX is $725.00, while the lowest price target for ARGX is $500.00. The average price target represents a forecasted downside of -1.08% from the current price of $665.60.

Get the Latest News and Ratings for ARGX and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for argenx and its competitors.

ARGX Analyst Ratings Over Time

Type	Current Forecast 1/16/24 to 1/15/25	1 Month Ago 12/17/23 to 12/16/24	3 Months Ago 10/18/23 to 10/17/24	1 Year Ago 1/16/23 to 1/16/24
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	1 Strong Buy rating(s)	1 Strong Buy rating(s)
Buy	18 Buy rating(s)	18 Buy rating(s)	17 Buy rating(s)	16 Buy rating(s)
Hold	3 Hold rating(s)	3 Hold rating(s)	4 Hold rating(s)	4 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	1 Sell rating(s)
Consensus Price Target	$658.39	$635.11	$550.44	$522.50
Forecasted Upside	-1.08% Downside	0.39% Upside	1.21% Upside	38.18% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

ARGX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

ARGX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

argenx Stock vs. The Competition

Type	argenx	Medical Companies	S&P 500
Consensus Rating Score	2.91	2.82	2.52
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	-1.08% Downside	24,950.25% Upside	14.85% Upside
News Sentiment Rating	Neutral News See Recent ARGX News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
1/14/2025	HC Wainwright 2 of 5 stars	Douglas Tsao Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$670.00 ➝ $717.00	+6.76%
1/14/2025	Truist Financial 2 of 5 stars	Joon Lee Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$660.00 ➝ $700.00	+3.93%
1/14/2025	JMP Securities 2 of 5 stars	Jason Butler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Market Outperform ➝ Market Outperform	$606.00 ➝ $696.00	+3.82%
1/7/2025	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$620.00 ➝ $725.00	+12.34%
12/19/2024	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$639.00 ➝ $723.00	+15.90%
12/3/2024	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform	$655.00	+4.97%
Get the Latest News and Ratings for ARGX and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for argenx and its competitors with MarketBeat's FREE daily newsletter.
11/21/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform ➝ Outperform	$646.00 ➝ $675.00	+14.38%
11/21/2024	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$675.00 ➝ $706.00	+19.29%
11/12/2024	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	A. Chen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Peer Perform ➝ Outperform	$697.00	+18.35%
11/5/2024	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	G. Farmer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Sector Perform ➝ Sector Outperform	$439.00 ➝ $715.00	+21.46%
11/4/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$640.00 ➝ $670.00	+12.61%
11/1/2024	Baird R W Subscribe to MarketBeat All Access for the recommendation accuracy rating	J. Beatty Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
11/1/2024	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$585.00 ➝ $665.00	+10.12%
11/1/2024	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Outperform ➝ Neutral	$515.00 ➝ $650.00	+10.86%
11/1/2024	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Minter Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform
10/17/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$512.00 ➝ $635.00	+16.89%
10/10/2024	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Brill Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Strong-Buy	$605.00	+16.23%
10/4/2024	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold
8/6/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	C. Pitman Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Equal Weight ➝ Overweight
6/24/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$535.00 ➝ $607.00	+40.57%
6/24/2024	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$485.00 ➝ $500.00	+14.82%
5/28/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$515.00 ➝ $510.00	+39.29%
12/12/2023	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$612.00 ➝ $641.00	+41.35%
10/2/2023	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$605.00 ➝ $628.00	+29.56%
7/24/2023	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Neutral	$480.00 ➝ $570.00	+3.93%
6/15/2023	Societe Generale Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Sell
5/5/2023	888 Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Maintains
3/3/2023	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform	$430.00 ➝ $435.00	+25.00%
3/3/2023	SVB Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$430.00 ➝ $435.00	+26.07%
1/25/2023	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform	$441.00 ➝ $458.00	+19.73%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 07:30 AM ET.

Should I Buy argenx Stock? ARGX Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Thursday, January 2, 2025. Please send any questions or comments about these argenx pros and cons to contact@marketbeat.com.

argenx
Bull Case

Here are some ways that investors could benefit from investing in argenx SE:

argenx SE reported earnings per share (EPS) of $1.39 for the latest quarter, significantly exceeding analysts' expectations of $0.10, indicating strong financial performance and potential for growth.
The company generated revenue of $588.88 million for the quarter, surpassing the consensus estimate of $543.29 million, showcasing its ability to outperform market expectations.
Institutional investors hold 60.32% of argenx SE's stock, reflecting confidence from large financial entities in the company's future prospects.
With a lead product candidate, efgartigimod, targeting multiple autoimmune diseases, argenx SE is positioned in a growing market with significant unmet medical needs.
The current stock price of argenx SE is approximately $201, which may present an attractive entry point for investors looking to capitalize on its growth potential.

argenx
Bear Case

Investors should be bearish about investing in argenx SE for these reasons:

Despite recent earnings success, argenx SE has a negative return on equity of 1.45%, indicating that the company is not currently generating profit relative to shareholder equity.
The company has a negative net margin of 2.11%, suggesting that it is not yet profitable, which could be a concern for potential investors.
Year-over-year, the company posted a loss of ($1.25) EPS during the same quarter last year, indicating volatility in its earnings performance.
Recent acquisitions by institutional investors may lead to increased volatility in stock price as these entities adjust their positions.
As a biotechnology firm, argenx SE faces inherent risks associated with drug development, including regulatory hurdles and the potential for clinical trial failures.

ARGX Forecast - Frequently Asked Questions

: According to the research reports of 22 Wall Street equities research analysts, the average twelve-month stock price forecast for argenx is $658.39, with a high forecast of $725.00 and a low forecast of $500.00.
: 22 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for argenx in the last twelve months. There are currently 3 hold ratings, 18 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ARGX shares.
: According to analysts, argenx's stock has a predicted downside of -1.08% based on their 12-month stock forecasts.
: Over the previous 90 days, argenx's stock had 3 upgrades and 2 downgrades by analysts.
: argenx has been rated by research analysts at Baird R W, Citigroup, Evercore ISI, Guggenheim, HC Wainwright, JMP Securities, JPMorgan Chase & Co., Oppenheimer, Piper Sandler, Robert W. Baird, Scotiabank, Truist Financial, Wedbush, Wells Fargo & Company, William Blair, and Wolfe Research in the past 90 days.
: Analysts like argenx more than other "medical" companies. The consensus rating score for argenx is 2.91 while the average consensus rating score for "medical" companies is 2.82. Learn more on how ARGX compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

This page (NASDAQ:ARGX) was last updated on 1/15/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

argenx (ARGX) Stock Forecast & Price Target